The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers
(White Plains, NY) - July 23, 2014 - Today's U.S.
Food and Drug Administration (FDA) approval of idelalisib to treat
patients with relapsed chronic lymphocytic leukemia (CLL), follicular
lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant
advance for patients with these blood cancers.
For full report follow this link:
http://www.lls.org/aboutlls/news/newsreleases/07232014_FDA_Approval_of_Idelalisib
 |
| go to LLS.org to find out how you can help |
No comments
Post a Comment